MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis.
BioMS Medical Corp, under license from the University of Alberta, is developing MBP-8298, a synthetic peptide analog of myelin basic protein, for the potential treatment of multiple sclerosis. Phase II and III clinical trials of MBP-8298 are underway.
Darlington
Cynthia
C
University of Otago, Department of Pharmacology and Toxicology, School of Medical Science, PO Box 913, Dunedin, New Zealand. cynthia.darlington@stonebow.otago.ac.nz
D000818:Animals; D015195:Drug Design; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D004676:Myelin Basic Protein / Q000138:chemical synthesis / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use*; D010330:Patents as Topic; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D004676:Myelin Basic Protein; D010446:Peptide Fragments; C526227:MBP-8298